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The emerging role of lncRNAs in
inﬂammatory bowel disease
Reza Yarani 1, Aashiq H. Mirza2, Simranjeet Kaur1 and Flemming Pociot1,3,4
Abstract
Dysregulation of long noncoding RNA (lncRNA) expression is linked to the development of various diseases. Recently,
an emerging body of evidence has indicated that lncRNAs play important roles in the pathogenesis of inﬂammatory
bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative Colitis (UC). In IBD, lncRNAs have been shown to
be involved in diverse processes, including the regulation of intestinal epithelial cell apoptosis, association with lipid
metabolism, and cell–cell interactions, thereby enhancing inﬂammation and the functional regulation of regulatory
T cells. In this review, we aim to summarize the current knowledge regarding the role of lncRNAs in IBD and highlight
potential avenues for future investigation. We also collate potentially immune-relevant, IBD-associated lncRNAs
identiﬁed through a built-by association analysis with respect to their neighboring protein-coding genes within IBD-
susceptible loci. We further underscore their importance by highlighting their enrichment for various aspects of
immune system regulation, including antigen processing/presentation, immune cell proliferation and differentiation,
and chronic inﬂammatory responses. Finally, we summarize the potential of lncRNAs as diagnostic biomarkers in IBD.
Introduction
Inﬂammatory bowel diseases (IBDs) are a group of
relapsing chronic inﬂammatory disorders that affect the
gastrointestinal (GI) tract. There are two major forms of
IBD: Crohn’s disease (CD) and ulcerative colitis (UC). CD
is characterized by patchy transmural inﬂammatory pat-
terns that are known to affect all layers of the intestinal
wall in any part of the GI tract. CD is more common in
young individuals; however, it may also occur in older
individuals. In general, it is accompanied by several
pathophysiological complications, including intestinal
ﬁbrosis, abscesses and ﬁstulas, abdominal pain, chronic
diarrhea with and without blood, mucus, and fever during
highly active disease1. UC is a disease of the mucosal
lining and is limited to the innermost layers with cryptitis
and crypt abscesses. Similar to CD, UC mainly affects a
younger population, and it is the most common form of
IBD2,3. While CD may affect any part of the GI system,
UC is limited to the large intestine, with the rectum
characterized as the main affected region. UC is less prone
to disease-associated complications3, and its course is
mild in many patients. Both subtypes demonstrate periods
of active disease followed by remission, of which each
state lasts for variable periods of time.
The etiology of IBD is not well understood; however,
comprehensive epidemiologic and genetic studies suggest
that IBD is a result of complex interactions between
genetics, immune dysregulation, and environmental fac-
tors, including lifestyle factors4. Genome-wide association
studies (GWAS) have identiﬁed 163 susceptibility loci in
more than 75,000 IBD patients and control individuals of
European descent5,6. While 110 loci were associated with
both phenotypes, 30 loci were unique to CD and 23 loci
were unique to UC5,6. Genetic predisposition studies have
shown an eightfold to tenfold higher risk of IBD in rela-
tives of CD and UC patients7. Twin studies have further
indicated that when a child has UC or CD, there are 9 and
26 times greater risks, respectively, for the second twin to
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develop these diseases8. However, the current GWAS data
seem to account for only 23% and 16% of the heritability
in CD and UC, respectively9.
The emergence of high-throughput sequencing tech-
nologies and advances in transcriptome biology have
revolutionized our understanding of gene function and
regulation. Remarkably, approximately 98% of the human
genome code for RNA molecules were previously not
annotated. These RNAs lack the capacity to code for
proteins and are therefore termed noncoding RNAs
(ncRNAs)10. ncRNAs have emerged as important reg-
ulators of gene expression at both the transcriptional and
post-transcriptional levels. A better understanding of
ncRNA mechanisms of gene regulation will increase our
knowledge of the physiological and pathological condi-
tions of development, regulation, and function in health
and disease processes, which, in turn, opens new avenues
for developing novel treatment strategies and nucleic acid
diagnostic biomarkers. In this review, we highlight the
emerging role of long ncRNAs (lncRNAs) as an important
class of ncRNAs in IBD. By reanalyzing our own datasets
together with published data, we present the biological
processes that are likely impacted by the signiﬁcantly
differentially expressed lncRNAs.
LncRNAs in IBD
LncRNAs are transcripts that are longer than 200
nucleotides and can be processed similar to protein-
coding mRNAs by RNA polymerase II11. To date, there is
no clear or ﬁnal classiﬁcation for lncRNAs. Based on the
proximity to protein-coding mRNAs, they can be assigned
to one or more categories, including sense and antisense
lncRNAs, bidirectional lncRNAs, intronic lncRNAs, and
long intergenic ncRNAs12. Our knowledge regarding the
number of lncRNA transcripts is also not consistent.
While studies have reported approximately 20,000
lncRNAs in the human genome13, according to the
NONCODE database’s latest version 5 (2018), there are
172,216 lncRNA transcripts and 96,308 lncRNA genes for
humans. These numbers of transcripts and genes are
substantially higher than the 28,468 lncRNA loci tran-
scripts and 15,779 lncRNA genes according to GEN-
CODE version 28 (November 2017 freeze, GRCh38) –
Ensembl 92. While these statistical disagreements could
simply be the result of the difference in updates or dis-
agreement regarding gene/transcript categorization, it
also reﬂects the lack of knowledge regarding this class of
macromolecules. The functions and mechanisms of action
of most lncRNAs are not fully understood; however, based
on the current ﬁndings, they exhibit diverse functional
roles, including the regulation of protein-coding genes by
chromatin remodeling, modulation of gene expression,
regulation of protein activity, localization, and
stability13–16. The role of lncRNAs in immune function
regulation and the progression of autoimmune diseases,
including type 1 diabetes17, rheumatoid arthritis18,
osteoarthritis19, psoriasis20, and asthma21, is gaining
increasingly more attention. Although the pathological/
diagnostic roles of microRNAs (miRNAs) as another class
of ncRNAs (small RNAs with a size of 20–25 nucleotides)
have been the focus of many IBD studies22–24, the
potential roles of lncRNAs remain largely unknown.
However, several recent studies have investigated the
association of dysregulated lncRNAs with both CD and
UC (summarized in Table 1) using colonic biopsies or
blood samples (or both) and have further highlighted their
roles in disease-related processes, including the regulation
of intestinal epithelial cells and inﬂammation.
DQ786243
One of the ﬁrst reports elucidating the role of lncRNAs
in IBD was the study by Qiao et al25. They showed that in
both disease active and inactive CD patients, DQ786243
lncRNA is upregulated compared to control subjects.
However, quantitative reverse transcription-PCR (RT-
PCR) indicated a signiﬁcant overexpression of DQ786243
in active CD patients compared with inactive CD patients
and healthy controls25. Subsequent overexpression of
DQ786243 in Jurkat cells has further shown that
DQ786243 can regulate the function of regulatory T
lymphocytes (Treg) through changes in the expression of
Treg-related cAMP response element-binding protein
(CREB) and fork head box P3 (Foxp3). It is established
that defective Tregs play an important role in CD
pathogenesis25. In addition, it has been suggested that
lncRNA DQ786243 regulates many biological processes,
including the cell cycle, apoptosis, metastasis, prolifera-
tion, and invasion, and G2/M cell cycle arrest in colorectal
cancer. More recently, the contribution of DQ786243 to
the proliferation and metastasis of colorectal cancer as an
oncogene that promotes tumor progression both in vitro
and in vivo has been elucidated. In vitro knockdown of
DQ786243 inhibits cell proliferation, invasion, and
migration26. Therefore, authors suggest that dysregulation
of DQ786243 is likely to play an important role in the
pathogenesis of both CD and colorectal cancers, whereas
its role in UC remains elusive. However, DQ786243 based
on the current build of the human reference genome
(GRCh38) has a changed annotation and is categorized as
a protein-coding gene.
CDKN2B-AS1 (ANRIL)
CDKN2B-AS1, which is also referred to as ANRIL, is a
3.8K nucleotide-long antisense lncRNA located in the
INK4 locus that has been identiﬁed within the p15/
CDKN2B-p16/CDKN2A-p14/ARF gene cluster and is
associated with multiple human diseases27. It is encoded
on the chromosome 9p2.3 region and has emerged as a
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regulatory molecule in many different human
diseases28–31. In contrast to cancers, where CDKN2B-AS1
showed signiﬁcant upregulation, in the IBD pathology
context, it shows a signiﬁcant downregulation13,32,33. In
our previous study, we found that out of 17 annotated
ANRIL isoforms, 8 major isoforms were downregulated in
inﬂamed UC colon pinch biopsies (fold change (FC) <
−7.9, −8.31, P value <0.05) and inﬂamed CD (FC <−2.7,
−2.97, P value <0.05) compared with noninﬂamed and
control tissues, respectively32. One of the eight isoforms
was circular variant (cANRIL), which was universally
downregulated in both inﬂamed CD and UC. It has been
shown that circular RNAs act as miRNA sponges and are
involved in stabilizing sense transcripts34. However, their
biological functions require further investigation to be
fully understood. Most recently, Haberman et al.33 iden-
tiﬁed CDKN2B-AS1 as one of the top 15 downregulated
lncRNAs in the ileum of treatment-naive early-onset CD
patients. They found 411 downregulated genes to be
coexpressed with this lncRNA in the cohort, which was
the highest coexpression number compared with the
other discovered lncRNAs. They further identiﬁed a sig-
niﬁcant decrease in the expression of CDKN2B-AS1 after
interleukin-1β (IL-1β) stimulation of Caco-2 cells.
CDKN2B-AS1 is enriched in the nuclear fraction, which
suggests a transcriptional regulatory role of this lncRNA
in intestinal epithelial cells. Moreover, in a gene expres-
sion proﬁling study that included eight UC, seven CD, and
seven control colonic samples, Rankin et al.35 found that
CDKN2B-AS1 lncRNA was signiﬁcantly downregulated
by 4.9-fold (P value: 0.041) in CD patient samples and 12-
fold (P value: 0.0009) in UC samples compared to control
samples. These ﬁndings were validated in independent
colon samples of 16 controls and 15 UC patients. Inves-
tigation of the CDKN2B-AS1 expression in several colon
epithelial cell lines, including NCM460, HCT116, and
DLD-1, showed a positive correlation with N-myc as an
important regulatory transcription factor, which was also
conﬁrmed in IBD patient samples (R2: 0.691; P value:
0.004304). Furthermore, while tumor necrosis factor-α
(TNF-α) and IL-1β treatment in the NCM460 cell line did
not affect the CDKN2B-AS1 expression, tumor growth
factor-β (TGF-β) treatment resulted in a twofold (P value:
0.0289) downregulation of this lncRNA. This observation
was fully compatible with the inverse correlation of TGF-
β1 expression in human samples (R2: 0.573; P value:
0.0255). Through gene pathway analysis, it has been fur-
ther shown that CDKN2B-AS1 lncRNA is associated with
lipid metabolism and cell–cell interactions36. However, to
elucidate the effect of dysregulated CDKN2B-AS1 on
colonic epithelial cell functions in IBD, for example,
apoptosis proliferation and barrier formation, further
studies are required.
Furthermore, Zhou et al.27 showed CDKN2B-AS1 reg-
ulates inﬂammatory responses as a novel component of
the nuclear factor-κB (NF-κB) pathway. Following
CDKN2B-AS1 knockdown in umbilical vein endothelial
cells, the expression of CDKN2A/B as a neighboring gene
was assessed. It is known that CDKN2A/B encode for the
cell cycle regulators p15INK4B and p16INK4A, which is
epigenetically regulated by CDKN2B-AS137. They found
that not only is cell growth arrested but the RNA levels of
p15INK4B and p16INK4A are also upregulated where
CDKN2B-AS1 is knocked down, which shows the
repressive effect of this lncRNA, as well as its regulatory
effect on cell proliferation. These ﬁndings were also
conﬁrmed by chromatin immunoprecipitation assay. They
further investigated the role of CDKN2B-AS1 under
pathological conditions by measuring its expression fol-
lowing proinﬂammatory cytokine (TNF-α) and growth
factor (VEGF165 and PDGF-BB) stimulation. While the
CDKN2B-AS1 expression showed a remarkable increase
(~5-fold) following TNF-α stimulation (in contrast to
ref. 35), no detectable change was identiﬁed following
growth factor treatment. Further RNA-sequencing indi-
cated that CDKN2B-AS1 silencing dysregulated the IL-6
and IL-8 expression under TNF-α treatment. They further
showed Yin Yang 1, which is a CDKN2B-AS1-binding
transcriptional factor, is required for IL-6/8 expression
under TNF-α treatment. The differences in the dysregu-
lation of CDKN2B-AS1 (and speciﬁcally cANRIL) are
highly fascinating and may be an interesting case for
further investigations to better understand the role of this
lncRNA in IBD pathogenesis.
IFNG-AS1
In a recent study, a subset of 31 differentially expressed
lncRNAs in UC patients (out of 767 evaluated lncRNAs)
was found to be within 250 kb from the IBD susceptibility
loci. IFNG-AS1 was signiﬁcantly differentially expressed
between UC and control colonic samples. A UC pheno-
type associated single-nucleotide polymorphism (SNP),
rs7134599, located adjacent to the inﬂammatory cytokine
interferon-γ (IFN-γ)38, seems to inﬂuence the IFNG-AS1
expression as expression quantitative trait loci. This
ﬁnding conﬁrms our previous study that showed IFNG-
AS1 was upregulated in inﬂamed UC vs. control subjects
(FC= 1.54) and noninﬂamed UC (FC= 1.52)32. Both
studies also showed IFNG-AS1 located adjacent to the key
inﬂammatory cytokine and ILs, such as IFN-γ, IL-22, and
IL-26. IFNG-AS1, which was originally named NeST or
Theiler’s murine encephalomyelitis virus persistence
candidate gene 1, is encoded on the opposite DNA strand
to the IFNG coding strand39 and is one of the most widely
studied lncRNAs. Through pathway analysis, an increase
in the expression of several upstream inﬂammatory
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response regulators, including IFN-γ, IL-1, IL-6, and
TNF-α, in UC patients with high IFNG-AS1 levels has
been elucidated. It has also been shown that IFNG-AS1
acts as an enhancer of inﬂammation by acting as a novel
regulator of IFN-γ inﬂammatory responses in CD4 T
(Th1) cells in UC patients with a high expression of
IFNG-AS138. This ﬁnding clearly suggests the importance
of the lncRNA IFNG-AS1 on the regulation of UC
disease-related inﬂammatory responses and suggests that
lncRNA can be used to differentiate active UC patients
from remission phase patients and the healthy population.
In addition, IFNG-AS1 has been implicated in other
autoimmune diseases, including Hashimoto’s thyroiditis
(HT) and asthma40–42. In HT, the IFNG-AS1 expression
was correlated with IFN-γ expression, T cell response,
and autoantibody titers40. The role of IFNG-AS1 in reg-
ulating the pathophysiology of several autoimmune-
related diseases, through similar or common processes
(e.g., regulating the expression of IFN-γ43,44), clearly
suggests the importance of lncRNAs for further analysis.
H19
H19 has been extensively investigated in cancer biol-
ogy45,46, while its role in IBD and other inﬂammatory or
autoimmune diseases has been less studied. The only
available study in IBD was performed by Chen et al. 47, in
which the role of H19 in UC development was investi-
gated, and the potential correlation of H19 with intestinal
epithelial barrier function was assessed. They showed that
the expression of H19 in colonic biopsies is negatively
correlated with the expression of vitamin D receptor
(VDR) in UC. VDR signaling plays an important role in
inﬂammation regulation48. One important mechanism in
volcanic intestinal inﬂammatory responses in UC devel-
opment and propagation has been demonstrated to be the
decrease in VDR expression47. Interestingly, over-
expression of H19 resulted in signiﬁcantly decreased
expression of the VDR (mean: 0.37; P < 0.05) and had a
destructive effect on the intestinal epithelial barrier
function by increasing permeability (in vitro model of
intestinal epithelium using Caco-2 monolayer) and
decreasing the expression of both main tight junction
proteins (ZO-1 and occludin)47. The study clearly sup-
ports a role of H19 lncRNA in the development of UC.
Zou et al.49 further showed that the effect of lncRNA H19
on intestinal epithelial barrier function is accomplished by
serving as a precursor for miRNA-675. The over-
expression of H19 increased the miRNA-675 abundance
(mean: 1.897; P < 0.01), which, in turn, downregulated the
adherent junction proteins E-cadherin and ZO-1 by
repressing and destabilizing their translation. They further
showed that targeted deletion of RNA-binding protein
HuR enhanced miRNA-675 production in the mucosa,
while increasing the level of this protein overexpressing
H19 prevented the stimulation of miRNA-675. Therefore,
they speculate H19 interacts with HuR and regulates its
function via the H19-encoded miRNA-675.
BC012900 and BC062296
H19 is not the only lncRNA that regulates epithelial cell
function. Intestinal epithelial cell apoptosis has also been
shown to be regulated by BC012900, which is also a UC-
associated lncRNA13. Among 329 upregulated lncRNAs
identiﬁed in active UC compared with healthy controls,
the three most signiﬁcantly upregulated lncRNAs were
BC012900, AK001903, and AK023330. Moreover, out of
126 downregulated lncRNAs, the three most signiﬁcantly
downregulated lncRNAs were the BC029135, CDKN2B-
AS1, and BC062296 transcripts. Among these lncRNAs,
the authors decided to perform further studies on
BC012900 expression. Thus, using quantitative PCR
(qPCR) and in situ hybridization, Wu et al.13 showed that
the lncRNA BC012900 is signiﬁcantly differentially
expressed in active UC compared to control subjects and
is localized in the nucleus. Stable overexpression of
BC012900 stimulated by inﬂammatory cytokines in epi-
thelial cell lines (HCT116 and HT29) resulted in a sig-
niﬁcant inhibition of cell proliferation and a signiﬁcant
increase in apoptosis that were positively correlated with
the expression level. Therefore, BC012900 may represent
an interesting target for future therapeutics or diagnostic
biomarker development in IBD. Among the investigated
lncRNAs, BC012900 was uniquely expressed in active UC
compared with other conditions. They also examined the
downregulated BC062296 localization in an epithelial cell
line and showed that it is highly abundant in the cyto-
plasm, which suggests its different regulatory activity
compared to BC012900 that was found in the nucleus.
However, in situ hybridization of BC062296 showed that
in contrast to BC012900, it is localized in both the cyto-
plasm and nucleus. Despite these ﬁndings and observa-
tions, ﬁve out of six top up- and downregulated lncRNAs
in this study were not found on the current build of the
human reference genome (GRCh38) or had changed
annotations as protein-coding genes, and BC062296 is the
only available lncRNA.
GUSBP2, AF113016, and DIO3OS
In a recent study by Chen et al.50, microarray screening
of CD patient plasma indicated more than 1200 and 1000
upregulated and more than 700 and 900 downregulated
lncRNAs and mRNAs, respectively. qRT-PCR evaluation
conﬁrmed the ﬁndings of the microarray screening, and
the highest up- and downregulated fold changes of
lncRNAs were shown to be for GUSBP2 and AF113016,
respectively. The study was the ﬁrst investigation to
evaluate plasma lncRNAs as biomarkers for the diagnosis
of CD. Primarily, 1988 and 2993 dysregulated lncRNAs
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and mRNAs between the CD and control groups were
identiﬁed in this study, which is substantially higher than
the 450 lncRNAs and 1100 mRNAs from our own study
in 201532. Moreover, in contrast to our previous study,
which showed that DIO3OS is downregulated32, in Chen
et al.’s study, this lncRNA was upregulated. Another dis-
agreement between the two studies was the lack of
overlap of dysregulated lncRNAs between our top 10
dysregulated results and their results. One potential
explanation for the differences in the studies could be the
different sources, as we used colonic samples and they
used plasma.
CCAT1 and UCA1
A 13 amino acid length neuropeptide, neurotensin (NT),
together with its high afﬁnity G protein-coupled receptor 1
(NTR1), are believed to promote the development of UC
and are expressed in the colon where they are upregulated
in animal colitis models and UC patients51–54. NT/
NTR1 signaling is involved in various colonic responses,
including proinﬂammatory responses, and regulates sev-
eral miRNAs associated with intestinal inﬂammation55,56.
Law et al.57 investigated the effect of NT stimulation on
the lncRNA proﬁle of human colonic epithelial cells
(NCM460) with NTR1 overexpression. In this study,
microarray data initially showed 150 and 155 down- and
upregulated lncRNAs, respectively. A comparison of the
lncRNAs identiﬁed in this study with the lncRNAs found
in the study by Padua et al.38 indicated that 13 lncRNAs of
305 are commonly dysregulated in these two studies. The
CCAT1 and UCA1 lncRNAs were found to be signiﬁcantly
overexpressed compared to those identiﬁed from human
UC patients and control subjects. Both UCA1 and CCAT1
lncRNAs play an important role in the pathogenesis of
many diseases, including various types of cancers and
inﬂammation-related disorders25,58–63. UCA1, also refer-
red to as CUDR, was ﬁrst detected in gastric juice. Its
abnormal expression is always accompanied by various
types of human cancers64,65. Studies have shown that these
two lncRNAs act as sponges for let-7 and miR-20466,67,
which are miRNAs downregulated by NT/NTR1
signaling in human colonic NCM460-NTR1 cells68. Fur-
thermore, CCAT1 modulated the HOXA1 expression
and promoted disease progression through sponging
miR-181a-5p in multiple myeloma69. Since limited data
exist to evaluate the role of NTR1 in human colonic epi-
thelial cells and its potential in UC pathophysiology (e.g.,
through the lncRNA–miRNA axes), further studies are
required57.
HNF4A-AS1, LINC01272, and RP11-44K6.2
In a new study, Haberman et al.33 characterized the
lncRNA landscape in the ileum of treatment-naive, that is,
not inﬂuenced by treatment, early-onset pediatric CD
patients. In this study, which was performed in pediatric
CD patients, 111 ileal biopsies were proﬁled. They showed
widespread dysregulation of more than 450 lncRNAs in
patients compared with healthy control subjects. For
prioritization of differentially expressed lncRNAs, fold
change differences between CD and healthy control sub-
jects were initially considered. From the top 15 up- and
downregulated lncRNAs, CDKN2B-AS1, HNF4A-AS1,
LINC01272, and RP11-44K6.2 were selected. These
lncRNAs were selected because they showed up in both
adult (from the same group’s previous study) and pedia-
tric cohorts, had the highest number of coexpressed
genes, and/or were unique. CDKN2B-AS1 was shown to
be one of the lncRNAs with the highest coexpressed
genes. CDKN2B-AS1 and HNF4A-AS1 showed a sig-
niﬁcant downregulation in the Ileum of the treatment-
naive cohort, whereas the downregulation of HNF4A-AS1
lncRNA was unique to this study and was not shown
elsewhere. In contrast to the previous two lncRNAs,
LINC01272 and RP11-44K6.2 showed a signiﬁcant upre-
gulation in this cohort, as well as in the adult colon. In
addition, LINC01272 demonstrated the highest number
of upregulated coexpressed genes of the top 15 upregu-
lated lncRNAs. A coexpression analysis was performed
with a well described, large set of genes using Pearson's
correlation analyses (r > 0.75) as a read out for the
potential functionality of the top 15 lncRNAs. Moreover,
they showed the tissue-speciﬁc expression of these
lncRNAs in biopsy samples using in situ hybridization and
suggest that lncRNAs demonstrate more tissue-speciﬁc
expression patterns compared with protein-coding genes.
While HNF4A-AS1 showed epithelial-speciﬁc expression,
LINC01272 showed speciﬁc myeloid expression. To
identify the biological processes, networks/pathways,
molecular functions, and phenotypes, functional annota-
tion enrichment analyses using groups of related genes
were performed for the selected lncRNAs. It has been
shown that LINC01272 is associated with immune acti-
vation functions, whereas HNF4A-AS1 is associated with
metabolic functions. HNF4A-AS1 and LINC01272
expression showed signiﬁcant correlations with more
severe mucosal injury when correlation is tested with
clinical disease activity indices and the severity of mucosal
injury. These ﬁndings were conﬁrmed using RT-qPCR in
the validation cohort. Finally, the authors suggest that the
signiﬁcant correlations between these lncRNA expres-
sions and mucosal tissue injury highlight the need to
further investigate the role of these two lncRNAs in CD
pathogenesis33.
KIF9‑AS1, LINC01272, and DIO3OS
In a very recent study, three lncRNAs, KIF9‑AS1,
LINC01272, and DIO3OS, were selected for evaluation as
potential diagnostic biomarkers for IBD70. LINC01272
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and DIO3OS were also identiﬁed by previous stu-
dies32,33,50. The expression levels of these lncRNAs in
colonic tissue and plasma samples of 84 UC, 84 CD, and
84 healthy individuals were investigated. The results
showed signiﬁcantly higher expression levels of KIF9‑AS1
and LINC01272 in UC/CD patients than in healthy indi-
viduals (P < 0.001) in both colonic and plasma samples.
The speciﬁcity and sensitivity of these two lncRNAs were
evaluated by a receiver-operating characteristic (ROC)
curve analysis in both UC and CD and compared with
healthy controls. The area under the ROC curve for
KIF9‑AS1 expression in CD and UC vs. healthy controls
was 0.811 (P < 0.0001) and 0.872 (P < 0.0001), respectively,
and 0.887 (P < 0.0001) and 0.777 (P < 0.0001), respectively,
for LINC01272. In contrast, the expression level of
DIO3OS was signiﬁcantly lower in CD/UC patients than
in healthy controls (P < 0.001) in both colonic and plasma
samples, which conﬁrms our previous ﬁndings32. The area
under the ROC curve between the DIO3OS expression in
CD and UC and healthy individuals was also reported as
0.794 (P < 0.0001) and 0.653 (P= 0.001), respectively.
Finally, the correlations between colonic biopsy and
plasma sample expression levels of these three lncRNAs
were investigated by Pearson's correlation coefﬁcient. The
results showed a positive correlation between the detected
expression in tissue and blood for all lncRNAs in both CD
and UC patients, and the ROC curve assessment also
conﬁrmed the diagnostic value of these lncRNAs.
Therefore, the authors suggest that these three lncRNAs
are robust candidates for being considered as IBD
biomarkers.
GAS5
LncRNAs can also cause resistance to treatment and
increase the severity of IBD. Growth arrest-speciﬁc tran-
script 5 (GAS5) is a lncRNA encoded at 1q25 and is
important in both nontransformed lymphocytes and T
cell lines’ cell cycle, normal growth arrest, and apopto-
sis71. In a recent study using both cell lines and IBD
patient samples, an increased level of lncRNA GAS5 was
identiﬁed after treatment with glucocorticoids (GCs). A
signiﬁcant increase in the level of GAS5 was shown to be
the rate-limiting factor in the remission of at least 20% of
IBD patients showing resistance to GC treatment72. GCs
are one of the ﬁrst line medications in the treatment of
both main types of IBD. However, considerable inter-
individual variability in the responses of IBD patients to
GC treatment has been documented73. GAS5 is an
lncRNA encoded by the GAS5 gene, which acts as the
riborepressor of the GC receptor74. Upregulated GAS5
binds to the DNA-binding domain of the GC receptor,
decoying the receptor away from its GC response element
and therefore results in GC resistance by inhibiting
transcriptional responses to GCs74. GAS5 is sensitive to
upframeshift 1, an RNA helicase for nonsense-mediated
mRNA decay (NMD), which suggests that some lncRNAs
can be degraded through NMD75. It has been shown that
GAS5 is differentially expressed in cell lines before and
after methylprednisolone treatment and is positively
correlated with drug resistance. A 4-week treatment of 19
pediatric IBD patients who were categorized as steroid-
resistant (SR), steroid-sensitive (SS), or steroid-dependent
(SD) showed that SR and SD patients had higher levels of
GAS5 expression than the SS group72. As a result of these
ﬁndings, the authors suggest that GAS5 expression can be
considered a candidate marker of GC resistance. Never-
theless, additional studies are required to elucidate the
exact role of this lncRNA in disease progression.
IBD-loci-associated lncRNAs
In a previous study of genome-wide transcriptome
proﬁling of lncRNAs and protein-coding genes in 96
colon pinch biopsies, we identiﬁed widespread dysregu-
lation of lncRNAs and protein-coding genes in inﬂamed
and noninﬂamed colon tissues in CD and UC compared
to healthy control subjects32. In total, 438 differentially
expressed lncRNAs in inﬂamed CD and 745 in inﬂamed
UC were identiﬁed compared with that in the control
group. In contrast, only 12 and 19 differentially expressed
lncRNAs were identiﬁed in cases of the noninﬂamed CD
and UC tissues, respectively, compared with the control
group. This study allows us to stratify CD from UC and
the healthy control population by highlighting the dif-
ferential expression of lncRNAs and the protein-coding
genes in inﬂamed CD and UC.
Moreover, an extensive landscape of functional muta-
tions in the noncoding genome has been identiﬁed from
GWAS with profound effects on lncRNA expression76.
SNPs can lead to complete or partial changes in lncRNA
functions. For example, they can result in the loss of
miRNA-mediated lncRNA degradation and consequently
increased lncRNA expression77. Interestingly, in our
previous study, signiﬁcant enrichment for 154 protein-
coding genes and 96 differentially expressed lncRNAs was
observed within the IBD GWAS loci32. The majority of
the GWAS signals map to the noncoding intronic and
intergenic regions5. The differentially expressed lncRNAs
colocalized with 44 IBD-risk variants and were also found
to be enriched within the IBD loci (P < 0.0001). These IBD
GWAS loci-associated lncRNAs included H19, SMIM25,
and IFNG-AS1, which were also identiﬁed as dysregulated
in IBD by other studies38,47,70.
Guilt-by-association analysis
Based on our previous study and a literature search, we
identiﬁed differentially expressed lncRNAs in IBD. Forty-
seven lncRNAs associated with IBD were identiﬁed
(Table 2). From our previous study, 46 lncRNAs (96
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Table 2 List of IBD-associated lncRNAs alongside their 100 kb up- and downstream neighboring protein-coding genes
ID Name PMID Protein-coding gene (100 kb)
Upregulated in CD and UC
ENSG00000234741 GAS5 28722800 CENPL, DARS2, KLHL20, RC3H1, SERPINC1, ZBTB37
ENSG00000227398 KIF9-AS1 29207070, 25991924 KIF9, KLHL18, SETD2
ENSG00000224397 SMIM25 29207070, 25991924 CEBPB
ENSG00000204044 SLC12A5-AS1 25991924 CD40, MMP9, NCOA5, PCIF1, SLC12A5, ZNF335
ENSG00000204261 PSMB8-AS1 25991924 HLA-DMB, HLA-DOB, HLA-DQA2, HLA-DQB2, PSMB8, PSMB9, TAP1, TAP2,
XXbac-BPG181M17.5, XXbac-BPG246D15.9
ENSG00000206337 HCP5 25991924 ATP6V1G2, ATP6V1G2-DDX39B, DDX39B, HLA-B, LTA, MCCD1, MICA, MICB,
NFKBIL1, TNF
ENSG00000226032 AL035530.1 25991924 RSPH3, TAGAP
ENSG00000249086 AC051649.1 25991924 LSP1, MRPL23, PRR33, SYT8, TNNI2, TNNT3
ENSG00000235641 LINC00484 25991924 AUH
ENSG00000261040 WFDC21P 25991924 CA4, HEATR6, USP32
ENSG00000268734 AC245128.3 25991924 FCAR, KIR2DL4, KIR3DL1, KIR3DL2, NCR1, NLRP2, NLRP7
ENSG00000269489 AL589765.6 25991924 C2CD4D, CELF3, LINGO4, MRPL9, OAZ3, RIIAD1, RORC, SNX27, TDRKH,
THEM4, THEM5
ENSG00000232807 AL137186.2 25991924 ANKRD16, FBXO18, GDI2, IL15RA, IL2RA
Downregulated in CD and UC
ENSG00000258498 DIO3OS 29207070, 25991924 DIO3
ENSG00000240498 CDKN2B-AS1 25991924 CDKN2A, CDKN2B, MTAP, RP11-145E5.5
ENSG00000233006 MIR3936HG 25991924 C5orf56, P4HA2, PDLIM4, SLC22A4, SLC22A5
ENSG00000259347 AC087482.1 25991924 SMAD3
ENSG00000259970 AC099668.1 25991924 AMIGO3, APEH, BSN, GMPPB, IP6K1, MST1, RNF123
ENSG00000264269 AC016866.1 25991924 DYM, SMAD7
Upregulated in UC
ENSG00000255733 IFNG-AS1 27492330, 25991924 IFNG, IL22, IL26, MDM1
ENSG00000130600 H19 27661667, 25991924 MRPL23, TNNT3
ENSG00000212978 AC016747.1 25991924 AHSA2, C2orf74, KIAA1841, PEX13, USP34
ENSG00000224220 AC104699.1 25991924 DNMT3A, DTNB
ENSG00000273782 UCA1 – CYP4F11, CYP4F2, OR10H1, OR10H3, OR10H5
ENSG00000254166 CASC19 –
ENSG00000225582 AC011193.1 25991924
ENSG00000229425 AJ009632.2 25991924
ENSG00000232698 AP001058.1 25991924 AIRE, C21orf33, DNMT3L, ICOSLG, PFKL, PWP2, TRAPPC10
ENSG00000237499 AL357060.2 25991924 TNFAIP3
ENSG00000264968 AC090844.2 25991924 CSF3, GSDMA, GSDMB, IKZF3, LRRC3C, MED24, ORMDL3, PSMD3, ZPBP2
ENSG00000251301 LINC02384 25991924 IL22, MDM1
ENSG00000254211 LINC01485 25991924 CPEB4
ENSG00000256940 AP001453.2 25991924 BAD, CCDC88B, DNAJC4, ESRRA, FERMT3, FKBP2, GPR137, KCNK4, MACROD1,
NUDT22, PLCB3, PPP1R14B, PRDX5, STIP1, TEX40, TRMT112, TRPT1, VEGFB
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transcripts) that were differentially expressed in CD and
UC and associated with IBD loci were selected (Gene
Expression Omnibus database: GSE67106)32. Of these
lncRNAs, 10 lncRNAs were deprecated or changed
annotation in the current genome build (GRCh38) and
were therefore removed. In addition, the three lncRNAs
most differentially expressed and not mapping on IBD loci
from our top 10 lists were added. Based on the literature
search, 19 signiﬁcantly differentially expressed lncRNAs
were selected, and ﬁve of these lncRNAs were not found
or changed annotations (e.g., DQ786243 and BC012900).
Therefore, 14 lncRNAs were selected, of which six were
common to our study. Three (KIF9-AS1, ANRIL
(CDKN2B-AS1), and DIO3OS) of the six common
lncRNAs were in our top 10 dysregulated lncRNAs. In our
study, in both CD and UC, KIF9-AS1 was in the top 10
upregulated and CDKN2B-AS1 was in the top 10 down-
regulated lncRNAs, whereas DIO3OS showed signiﬁcant
downregulation only in the CD patients. Neither of these
three lncRNAs are associated with IBD susceptible loci.
The guilt-by-association analysis of these 47 IBD
lncRNAs was performed by retrieving protein-coding
genes (100 kb up/downstream) in the vicinity of these
differentially expressed lncRNAs. One hundred ninety-
three protein-coding genes were retrieved and used for
gene ontology and pathway-based clustering using
ClueGO in CytoScape78. By performing functional anno-
tation and gene ontology analysis, we identiﬁed an
enrichment for various immune system processes in the
GO analysis and an enrichment for primary immunode-
ﬁciency and various cytokine-mediated signaling path-
ways in the pathway analysis (Fig. 1). The detailed
description of all enriched terms and pathways, including
individual term and group P values, are provided in
Supplementary Table 1. The enriched GO terms included
negative regulation of immune system process, lympho-
cyte activation, leukocyte differentiation, the JAK-STAT
cascade and antigen processing, and presentation via the
major histocompatibility complex protein complex. The
enriched pathways included TGF-β signaling, IL-17
Table 2 continued
ID Name PMID Protein-coding gene (100 kb)
ENSG00000257069 AP001453.3 25991924 BAD, CCDC88B, DNAJC4, ESRRA, FERMT3, FKBP2, GPR137, KCNK4,
NUDT22, PLCB3, PPP1R14B, PRDX5, RPS6KA4, STIP1, TEX40, TRMT112, TRPT1,
VEGFB
Downregulated in UC
ENSG00000227036 LINC00511 25991924 SLC39A11
ENSG00000170858 LILRP2 25991924 KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL3, LILRB1, LILRB4
ENSG00000258867 LINC01146 25991924 GALC, GPR65, KCNK10
ENSG00000261266 AC008870.3 25991924 CHP2, DCTN5, ERN2, NDUFAB1, PALB2, PLK1
ENSG00000184809 B3GALT5-AS1 26937624 B3GALT5, SH3BGR
ENSG00000267130 AC008738.2 25991924 CEBPA, CEBPG, LRP3, PEPD, SLC7A10
Upregulated in CD
ENSG00000241549 GUSBP2 27217703
ENSG00000253838 AC007991.2 25991924 ADAM2, IDO1, IDO2
Downregulated in CD
ENSG00000278217 MALAT1 27217703 AP000769.1, EHBP1L1, FAM89B, FRMD8, KCNK7, LTBP3, MAP3K11, SCYL1,
SIPA1, SSSCA1
ENSG00000229005 HNF4A-AS1 29361088 FITM2, GDAP1L1, HNF4A, R3HDML, TTPAL
ENSG00000232693 AC012370.1 25991924 SPRED2
Upregulated in CD vs UC
ENSG00000238164 TNFRSF14-AS1 25991924 FAM213B, HES5, MMEL1, PANK4, PLCH2, TNFRSF14, TTC34
ENSG00000269667 AC092723.1 25991924 IRF8
Forty-seven lncRNAs including 8 lncRNAs only from literature, 6 lncRNAs both from literature and our study, and 33 lncRNAs only based on our previous study were
selected. Up- and downregulated lncRNAs in CD and UC, UC, CD and CD vs. UC (only upregulated) are categorized
Note: The non-IBD loci-associated lncRNAs are in bold
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signaling, allograft rejection and antigen processing, and
presentation. Although the precise role of lncRNAs in
IBD is poorly understood and must be further investi-
gated, in line with our ﬁndings, compelling emerging
evidence highlights the important role of ncRNAs in
modulating immune responses and inﬂammatory cas-
cades32,33,79–83.
The differential expression of lncRNAs in disease states
is a valuable indication of phenotypic changes, which may
have correlations with disease evolution. However,
expression per se does not indicate the lncRNA’s func-
tionality. Genomic conservation in other organisms sug-
gests the importance of studied sequences for
evolutionary pressure to preserve them, which may indi-
cate functionality. Only 8 of the 47 IBD-associated
lncRNAs evaluated here had orthologs in mouse and/or
other organisms based on the HUGO comparison of
orthology predictions (HCOP) database84 (Table 3). It is
believed that due to the rapid evolvement of lncRNAs in
species separated by >50 million years of evolutionary
divergence, more than 70% of them have no sequence
similar orthologs85. Although lncRNAs are poorly con-
served in general, conservation of lncRNAs at the struc-
tural and functional levels might be substantially higher
than their sequences. This is well established for other
RNA molecules86. Our data indicate that while seven of
eight lncRNAs have been conserved across mammalian
species, GAS5 is the only one that is also conserved in
zebraﬁsh. However, poor genome annotations of many of
the available organisms and technical errors in sample
preparation may cause false negatives in searching for
ortholog sequences in other organisms. Moreover, as
noted, most of the conserved loci are in mice rather than
other organisms that have a closer evolutionary relation-
ship to humans. This may reﬂect better ncRNA annota-
tion or more available data for the mouse genome than
other genomes.
The guilt-by-association analysis conﬁrms previous
studies in which an overlap between the genetic loci
associated with the risk for IBD and a large number of
annotated lncRNAs was demonstrated32,87. In addition, it
shows a pivotal role of lncRNAs in immune cells and
system function regulation and the progression of IBD
potentially through gene regulation. Consistent with these
ﬁndings, it has been shown that IBD loci were signiﬁcantly
enriched and overlap active regulatory regions in primary
intestinal epithelium and immune cells88. As IBD is an
immune-mediated disease, these data not only reempha-
size the importance of immune related processes in the
disease pathogenesis and progression but also suggest the
potential of signiﬁcantly differentially expressed lncRNAs
as biomarkers.
LncRNAs as biomarkers for IBD
Currently, there is no single gold standard test available
for the diagnosis of IBD. The routine diagnosis for IBD
includes clinical symptom assessment combined
with endoscopic examination, histology, serology, and
radiology. Most of the current biomarkers reﬂect gen-
eralized inﬂammation and are not disease speciﬁc, which
may lead to delayed treatment and further disease
progression89.
Fig. 1 The guilt-by-association analysis of 47 IBD lncRNAs was performed by retrieving protein-coding genes (100 kb up/downstream) in
the vicinity of these lncRNAs. One hundred ninety-three protein-coding genes were retrieved and used for gene ontology and pathway-based
clustering using ClueGO in CytoScape. a shows the most signiﬁcant biological process (BP) categories and c shows the most signiﬁcant pathways
based on KEGG annotations associated with the protein-coding genes. b, d Only the representative terms for each cluster as selected by ClueGo
analysis based on the total number of genes and %Genes/Term are reported. The total number of genes and %Genes/Term are listed next to the
representative term. The P values for each group are denoted by *P value < 0.05) and **P value < 0.01)
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LncRNAs have proven to be valuable diagnostic mar-
kers of various diseases90,91 because they are easy to
obtain, stable, quick to detect by common molecular
biology techniques (e.g., qRT-PCR), quantiﬁable, cost
effective, and tissue/disease speciﬁc90,92,93. In IBD, in all
discussed studies, the lncRNA proﬁle data of colonic
biopsy and blood samples show a clear difference between
disease and healthy groups. Therefore, these ﬁndings
should enable us to stratify not only the IBD subtypes but
also the active and inactive states of the disease. However,
additional studies are required to conﬁrm these ﬁndings
and identify new lncRNAs. Noninvasive body ﬂuid-based
lncRNA biomarkers provide an excellent window of
opportunity to signiﬁcantly improve our ability to diag-
nose and monitor IBD activity. While there are studies
addressing the dysregulation of lncRNA proﬁles in the
blood of IBD patients, it is evident that more data con-
cerning dysregulated lncRNAs in other body ﬂuids,
including saliva, gastric juice, and urine, are needed.
Furthermore, the complexity of the pathological process
of IBD and the limited knowledge available suggest that a
single lncRNA biomarker may not be suitable for the
diagnosis of IBD or its subtypes. Thus, a combination of
several lncRNA candidates from different tissue sources,
together with available biomarkers, may be necessary to
provide a precise diagnosis. There are insufﬁcient studies
regarding the differentially expressed lncRNAs between
early-stage and active IBD patients who can be used for
early diagnosis. Overall, more studies with larger investi-
gation/validation cohorts of IBD patients for both colonic
biopsies and body ﬂuids should be performed to increase
the likelihood for introducing robust and reliable
lncRNAs as biomarkers for IBD.
Conclusion and future direction
Within the past few years, new insights into the func-
tions of lncRNAs in many diseases have emerged. Many
lncRNAs have shown promising translatable potential for
clinical applications from prediction and diagnosis to
treatment and monitoring of patients. However, in IBD
settings, additional studies with larger cohorts and better
techniques are required to have a higher likelihood of
obtaining more signiﬁcant outcomes. With a small
population size, the obtained data are dispersed; therefore,
the retrieved proﬁle contains more lncRNAs, many of
which may have little or no real association with the
disease phenotype. In addition, the need for more
advanced and robust techniques to detect lowly expressed
lncRNAs and further studies to limit or address the
impact of confounding factors, such as subject number,
technical errors, and patient race, are as highly important
as the previously outlined issues. At this stage, most of the
studies in IBD merely show associations of lncRNAs with
disease and/or disease subphenotypes and do not provide
insight into the underlying mechanisms of lncRNAs in
disease development.
To explore the role of lncRNAs in IBD pathogenesis and
support their potential as biomarkers or therapeutic tar-
gets, further comparisons of body ﬂuids and colonic
tissue-speciﬁc lncRNAs, in addition to more thorough
molecular and structure–activity relationship studies are
necessary. There is only one study available that addressed
this critical comparison for biomarker discovery.
Although only three selected lncRNAs using only qPCR
were investigated, a positive correlation between the
detected lncRNAs from tissue and blood was detected70.
lncRNAs hold substantial promise as therapeutic targets
Table 3 List of lncRNAs that have orthologs in other organisms based on HCOP database
Name Genome position (human) Classiﬁcation (human) Orthologs (Ensembl/Entrez ID)
GAS5 Chr1:173,863,900–173,868,882 Processed transcript • ENSMUSG00000053332; 14455 (mouse)
• 81714 (rat)
• 101883732 (zebraﬁsh)
SMIM25 Chr20:50,267,486–50,279,795 lincRNA • 100615910 (chimpanzee)
WFDC21P Chr17:60,083,566–60,091,885 Processed transcript • ENSMUSG00000051748; 66107 (mouse)
DIO3OS Chr14:101,552,221–101,560,431 LincRNA • ENSMUSG00000113581; 353504 (mouse)
• 102546650 (rat)
IFNG-AS1 Chr12:67,989,445-68,234,686 Antisense • ENSMUSG00000112230; 103214 (mouse)
H19 Chr11:1,995,163–2,001,470 LincRNA • ENSMUSG00000000031; 14955 (mouse)
UCA1 Chr19:15,834,730–15,834,804 MiscRNA • ENSMMUG00000045194 (macaque)
MALAT1 Chr11:65,502,914–65,503,008 MiscRNA • ENSMUSG00000098462; ENSMUSG00000098869 (mouse)
• ENSPTRG00000045406 (chimpanzee)
• ENSMMUG00000047687 (macaque)
Note: The non-loci-associated lncRNAs are in bold
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in different disease settings;94,95 however, there is an
insufﬁcient number of focused studies that address this
issue in IBD. It is important to keep in mind that asso-
ciations or correlations of lncRNAs with disease pheno-
types do not provide information on the underlying
molecular disease mechanisms per se. To unravel these
mechanisms, more thorough mechanistic and functional
studies that aim to investigate the biological roles are
needed. However, undoubtedly in the near future, more
research will investigate the therapeutic effect of targeting
lncRNAs in IBD.
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